The Global Liver Institute (GLI) has name Dr Brian Harvey as executive vice president of scientific and regulatory affairs, having been a member since its founding in 2014.
In the role, Harvey will support and guide GLI on scientific, medical and regulatory matters, supporting the institute’s aim to promote innovation, encourage collaboration between diverse partners and optimise approaches to beat liver diseases.
Founder and president of GLI, Donna Cryer, said: “Brian not only has a wealth of medical knowledge and experience as a practicing physician, but, having worked within both U.S. Food and Drug Administration and at several leading pharmaceutical companies, he brings to GLI extensive industry experience that will help us identify opportunities to transform the field of liver disease.”
Harvey joins from Pfizer, where he most recently served as VP of US regulatory strategy, covering pharma and biologics across all therapy areas. Prior to joining Pfizr, he held the role of VP of US regulatory policy for Sanofi-Aventis.
Harvey has also previously held positions at the FDA, including working as director of the regulator’s division of gastroenterology products.
Commenting on his appointment, Harvey said: “I’m proud to join Donna and her team as they apply their new formula for advocacy and collaboration to tackle the complex public health issues surrounding liver disease.
“Liver disease affects over 30 million people in this country alone, and I believe GLI’s approach to advocacy can not only raise awareness of liver disease, but rapidly develop and disseminate solutions that can improve the lives of patients and their families.”